Sign In
Section Navigation
Common TitleM97-765
Official Title Phase I/II Study of Lopinavir (ABT-378)/Ritonavir in Protease Inhibitor Experienced HIV-Infected Patients
Phase Phase I
ClinicalTrials.gov NCT00004580
Categories PharmacologyTreatment-ExperiencedAdverse EffectsResistance/Virological Failure
Funding
IndustryAbbott
References
  • Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607.
    [PubMed Abstract]
  • Kempf DJ, Isaacson JD, King MS, et al. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-9.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.